Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$78.76 USD

78.76
901,673

-0.53 (-0.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $78.78 +0.02 (0.03%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Earnings Preview: Hologic (HOLX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?

by Zacks Equity Research

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in second-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View

by Zacks Equity Research

Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

by Sanghamitra Saha

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Sweta Jaiswal, FRM headshot

Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress

by Sweta Jaiswal, FRM

It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.

Sweta Jaiswal, FRM headshot

Healthcare ETFs Gain on Rising Demand for COVID-19 Tests

by Sweta Jaiswal, FRM

A growing demand for COVID-19 tests has indulged major healthcare place in the race to develop competent testing kits.

Urmimala Biswas headshot

4 Stocks Countering Coronavirus Battle With Testing Kits

by Urmimala Biswas

While the market bloodbath is showing no signs of dissipating any time soon, investors might keep an eye on certain genetic testing and medical device companies.

Sriparna Ghosal headshot

FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)

by Sriparna Ghosal

These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.

Sriparna Ghosal headshot

FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus

by Sriparna Ghosal

These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.

Urmimala Biswas headshot

3 Medical Stocks Poised to Trounce Market on Coronavirus Scare

by Urmimala Biswas

Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.

Hologic (HOLX) Gets EUA for Its Coronavirus Detecting Test

by Zacks Equity Research

Hologic (HOLX) receives support from the government as a EUA for its molecular test to detect novel coronavirus on its Panther Fusion system.

Here's Why You Should Add Hologic Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on its strong segmental performance in Q1.

Hologic (HOLX) Down 12.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hologic Expands Panther Portfolio With New Product Offerings

by Zacks Equity Research

Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.

Here's Why You Should Hold on to Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on its strong segmental and international results in Q1.

Hologic (HOLX) Q1 Earnings Meet, Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) exhibits robust growth in first-quarter fiscal 2020, fueled by strong performance in the majority of its segments.

Hologic (HOLX) Matches Q1 Earnings Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 0.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More

by Urmimala Biswas

A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

by Zacks Equity Research

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Hologic (HOLX) gains from several positive developments.

Sanghamitra Saha headshot

6 Sector ETFs & Stocks to Watch on December U.S. Inflation

by Sanghamitra Saha

These sector ETFs and stocks should benefit from decent price gains in the month of December.

Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan

by Zacks Equity Research

Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.

DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Hologic (HOLX) Divests Cynosure to Focus on Women's Health

by Zacks Equity Research

Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.